Dishman Pharma shines on receiving license to make TB drug

Dishman Pharmaceuticals & Chemicals is currently trading at Rs 283.95, up by 19.85 points or 7.52% from its previous closing of Rs 264.10 on the BSE.

The scrip opened at Rs. 263.00 and has touched a high and low of Rs 288.90 and Rs. 260.00 respectively. So far 645552 shares were traded on the counter.

The BSE group 'B' stock of face value Rs 2 has touched a 52 week high of Rs 288.90 on 22-Sep-2015 and a 52 week low of Rs 102.80 on 17-Dec-2014.

Last one week high and low of the scrip stood at Rs 288.90 and Rs 247.00 respectively. The current market cap of the company is Rs 2296.64 crore.

The promoters holding in the company stood at 61.40% while Institutions and Non-Institutions held 18.40% and 20.20% respectively.

Dishman Pharmaceuticals and Chemicals (Dishman), a leading global manufacturer of pharmaceutical active ingredients, has received a license agreement from Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) to produce the Active Pharmaceutical Ingredient (API) of SIRTURO (bedaquiline), a medicine used in the treatment of Multi-Drug Resistant Tuberculosis (MDR-TB).

Tuberculosis (TB) is a major public health concern in India with the World Health Organization estimating there are more than 2.8 million cases of TB. In particular, the burden of MDR-TB in India, is among the most significant in the world with an estimated 64,000 cases, and for those diagnosed with this deadly disease, fewer than half are treated successfully. In 2008 Janssen had contracted Dishman to conduct full chemical synthesis of this API at their manufacturing facility in Bavla, India. Janssen subsequently registered Dishman as a manufacturer of API with the USFDA, European Medicines Agency and several other Asian regulatory authorities. Recently, Dishman has started supplying Janssen with the global demand of this API.

Dishman is a leading global outsourcing partner for the pharmaceutical industry, offering a rich portfolio of development, scale-up and manufacturing services that straddle the entire pharmaceutical value chain. The company offers cost-effective, high-quality research, development and manufacturing services that include production and supply of tailor-made, high-quality Intermediates and generic APIs to the global pharmaceutical industry. Its global presence includes multiple manufacturing sites in Europe, India, and China - making it one of the most geographically diversified players in the industry.